Quest Diagnostics Incorporated (NYSE:DGX – Get Rating)’s share price hit a new 52-week low on Tuesday . The stock traded as low as $123.14 and last traded at $123.14, with a volume of 1965 shares changing hands. The stock had previously closed at $125.59.
Analysts Set New Price Targets
Several research firms have recently issued reports on DGX. Morgan Stanley reissued an “equal weight” rating and issued a $142.00 price target on shares of Quest Diagnostics in a research note on Monday, August 22nd. StockNews.com cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, September 15th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $148.50.
Quest Diagnostics Stock Performance
The company has a current ratio of 1.54, a quick ratio of 1.42 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average price is $132.19 and its two-hundred day moving average price is $135.43. The company has a market cap of $14.20 billion, a P/E ratio of 10.13 and a beta of 1.01.
Quest Diagnostics Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 19th. Stockholders of record on Tuesday, October 4th will be given a dividend of $0.66 per share. The ex-dividend date of this dividend is Monday, October 3rd. This represents a $2.64 annualized dividend and a dividend yield of 2.17%. Quest Diagnostics’s dividend payout ratio (DPR) is 21.96%.
In other Quest Diagnostics news, Director Timothy M. Ring sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $136.04, for a total value of $272,080.00. Following the completion of the transaction, the director now directly owns 23,933 shares in the company, valued at $3,255,845.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.70% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Quest Diagnostics by 5.8% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 11,867 shares of the medical research company’s stock worth $1,624,000 after buying an additional 654 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Quest Diagnostics during the first quarter worth approximately $524,000. Argent Trust Co boosted its holdings in shares of Quest Diagnostics by 1.4% during the first quarter. Argent Trust Co now owns 27,237 shares of the medical research company’s stock worth $3,728,000 after purchasing an additional 374 shares during the period. Pinebridge Investments L.P. boosted its holdings in shares of Quest Diagnostics by 480.4% during the first quarter. Pinebridge Investments L.P. now owns 98,916 shares of the medical research company’s stock worth $13,538,000 after purchasing an additional 81,873 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Quest Diagnostics by 20.4% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 8,513 shares of the medical research company’s stock worth $1,165,000 after purchasing an additional 1,440 shares during the period. 88.87% of the stock is currently owned by institutional investors and hedge funds.
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
- Get a free copy of the StockNews.com research report on Quest Diagnostics (DGX)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.